Clinical Trial: Selinexor and Pacritinib in JAK Inhibitor-naive MF Patients With Cytopenias

U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07447817) titled 'Selinexor and Pacritinib in JAK Inhibitor-naive MF Patients With Cytopenias' on Feb. 25.

Brief Summary: This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naive patients with anemia and thrombocytopenia.

Study Start Date: May 04

Study Type: INTERVENTIONAL

Condition: Myelofibrosis Post-polycythemia Vera Myelofibrosis Post-essential Thrombocythemia Myelofibrosis

Intervention: DRUG: Pacritinib

Pacritinib 200mg twice a day (BID) by mouth (PO)

DRUG: Selinexor

Selinexor 60mg once weekly (QW) by mouth (PO)

Recruitment Status: NOT_YET_RECRUITING

Sponso...